Loading patent…
AssigneeProsidion Limited
InventorsHans-Ulrich Demuth, Konrad Glund, J. Andrew Pospisilik, Kerstin Kuehn-Wache
Estimating the term…
The present invention discloses methods for therapeutically treating mammals, including but not limited to humans, to increase the relative insulin producing performance of endogenous pancreatic β-cells, to cause differentiation of pancreatic epithelial cells into insulin producing β-cells, to improve muscle sensitivity to insulin and other weight control efforts by the chronic oral administration of a DP IV-inhibitor. The administration causes the active form of GLP-1 and other non-nutrient stimulated growth hormones to remain biologically active longer under physiological conditions. The extended presence of such hormones, in particular in the pancreatic tissue can also facilitate differentiation and regeneration of the β-cells already present that are in need of repair.
A method for improving β-cell capacity to secrete insulin in response to increased glucose levels comprising increasing the availability of islet cell growth hormone to pancreatic cells wherein said islet cell growth hormone circulates at a level which is substantially unresponsive to acute changes in glucose level.
A method for stimulating the differentiation of pancreatic cells to islets of Langerhans cells comprising increasing the availability of at least one of the islet cell growth hormones which is centrally and/or peripherally stimulated.
A method for increasing a mammal's β-cells' ability to secrete insulin or differentiation of pancreatic cells to β-cells in a mammal comprising increasing within said mammal the availability of islet cell growth hormones which are responsive to central and/or peripheral stimulation and substantially unresponsive to acute changes in circulating nutrient levels in said mammal.
A method for causing an effect in a mammal selected from the group consisting of decreasing the rate of chronic weight gain, decreasing weight, improving the sensitivity of muscles to insulin, reducing said mammal's desire for food, decreasing the time to reaching a state of satiety in a mammal following the initiation of food intake, and decreasing the level of obesity, said method comprising repeatedly orally administering to said mammal a therapeutically effective dose of an inhibitor of DP IV enzymatic activity.
Dependencies are inferred from the claim text.